1. Introduction

Biotechnology approvals involve legal, administrative, scientific and constitutional decision-making concerning genetically modified organisms (GMOs), gene-editing technologies, biological medicines, vaccines, stem-cell research, synthetic biology, clinical trials and other advanced biological interventions.

The monarchy and executive may have different constitutional roles in determining whether biotechnology research, products or commercial activities should be permitted.

In constitutional monarchies, the monarch generally performs formal constitutional functions, while the executive government exercises actual administrative and regulatory authority. The executive is responsible for implementing legislation, supervising regulatory agencies, granting approvals, imposing safety conditions and protecting public health and the environment.

The central legal question is how constitutional authority, scientific expertise, democratic accountability and regulatory independence should be balanced when biotechnology activities may affect human life, biodiversity and future generations.

An important distinction is that monarchy does not ordinarily mean direct royal control over scientific approvals. In modern constitutional systems, biotechnology decisions are generally made under statutory authority by ministers, departments and specialist regulatory agencies.

2. Meaning of Monarchy in Biotechnology Governance

Monarchy refers to a constitutional system in which a hereditary sovereign, such as a king or queen, serves as the head of state.

Its involvement in biotechnology governance is usually indirect and constitutional rather than scientific.

Its possible functions include:

Formal assent to legislation: Giving royal assent to biotechnology legislation passed by Parliament.

Constitutional appointment: Formally appointing ministers or other public officials in accordance with constitutional conventions.

Executive formalities: Performing formal governmental acts on the advice of responsible ministers.

Constitutional continuity: Representing institutional stability during changes in government.

Ceremonial representation: Supporting national scientific institutions and public-interest initiatives without independently determining regulatory outcomes.

The monarch ordinarily cannot independently authorize a GMO, approve a clinical trial or override a statutory biosafety regulator.

3. Role of the Executive in Biotechnology Approvals

The executive consists of the Prime Minister, Cabinet, relevant ministers, government departments and administrative authorities exercising powers under legislation.

Its role is substantially more important than that of the monarch in biotechnology regulation.

A. Policy formulation

The executive establishes national biotechnology policies concerning:

Genetic engineering and genome editing.

Agricultural biotechnology and GM crops.

Human genetic research.

Stem-cell research and regenerative medicine.

Vaccine development and biological medicines.

Synthetic biology and gene-drive technologies.

Biological security and laboratory containment.

The executive must ensure that biotechnology policy balances scientific innovation with public safety, environmental protection and ethical considerations.

B. Granting regulatory approvals

The executive establishes and supervises regulatory mechanisms for approving biotechnology activities.

For example, approval processes may involve:

Submission of a scientific and technical application.

Examination of laboratory safety standards.

Environmental and human-health risk assessment.

Review by scientific committees.

Public consultation, where required.

Ministerial or regulatory approval.

Post-approval monitoring and compliance inspections.

The executive must act within the authority conferred by legislation. Political convenience cannot replace scientific evaluation or statutory requirements.

C. Supervision of regulatory agencies

The executive supervises specialist authorities responsible for biotechnology governance.

In India, important institutions include:

Genetic Engineering Appraisal Committee (GEAC).

Review Committee on Genetic Manipulation (RCGM).

Institutional Biosafety Committees (IBSCs).

Central Drugs Standard Control Organisation (CDSCO).

Department of Biotechnology (DBT).

National Biodiversity Authority (NBA).

These institutions perform different regulatory functions. The executive must coordinate their activities without unlawfully interfering with independent scientific assessment.

D. Public health and environmental protection

The executive must ensure that biotechnology approvals do not create unacceptable risks to:

Human health.

Agricultural biodiversity.

Native species.

Food security.

Ecological systems.

Future generations.

The precautionary principle is particularly important where scientific uncertainty exists and potentially irreversible environmental consequences are possible.

E. Accountability and transparency

The executive must provide legally sufficient reasons for important regulatory decisions, disclose information where required, maintain appropriate records and permit judicial review.

An approval based on undisclosed political pressure, irrelevant considerations or inadequate scientific assessment may be challenged before a competent court.

4. Constitutional and Statutory Framework in India

India is a republic, not a monarchy. Therefore, the Indian President does not perform the functions of a hereditary sovereign.

Under Articles 52 and 53 of the Constitution, the President is the constitutional head of the Union, while executive authority is exercised within the constitutional framework.

Articles 74 and 75 establish the Council of Ministers and its responsibility to the Lok Sabha.

The biotechnology approval framework primarily operates through the following laws.

Rules, 1989

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, are particularly important.

They establish a regulatory structure for research, manufacture, use, import, export and storage of specified hazardous microorganisms and genetically engineered organisms.

The GEAC operates under this framework and has important approval responsibilities, including large-scale trials and environmental release of GMOs.

Ministry of Environment

Constitutional position

The executive cannot exercise unlimited authority merely because biotechnology involves national development or scientific advancement.

Its decisions must comply with:

Article 14: Equality and protection against arbitrary governmental action.

Article 19: Applicable freedoms and reasonable restrictions.

Article 21: Protection of life and personal liberty.

Article 48A: Protection and improvement of the environment.

Article 51A(g): Fundamental duty to protect the natural environment.

These provisions provide constitutional standards for examining biotechnology governance.

5. Role of Monarchy and Executive in the United Kingdom

The United Kingdom provides a useful example of constitutional monarchy and executive biotechnology governance.

The monarch is the formal head of state, while the Prime Minister and Cabinet exercise governmental authority.

A. Royal assent to biotechnology legislation

Biotechnology legislation passed by Parliament requires royal assent to become law.

Examples include:

Environmental Protection Act 1990.

Genetic Technology (Precision Breeding) Act 2023.

Relevant statutory regulations governing genetically modified organisms.

Royal assent is a constitutional formality. The monarch does not independently assess the scientific merits of biotechnology legislation.

B. Executive responsibility

The Secretary of State for Environment, Food and Rural Affairs has important responsibilities concerning environmental releases of GMOs in England.

The relevant legislation includes:

Environmental Protection Act 1990.

Genetically Modified Organisms (Deliberate Release) Regulations 2002.

Genetically Modified Organisms (Contained Use) Regulations 2014.

The regulatory system requires risk assessments, notifications and, where prescribed, governmental consent before activities can proceed.

GOV.UK+2

C. Role of scientific authorities

The Health and Safety Executive (HSE), Advisory Committee on Releases to the Environment (ACRE) and other specialist bodies provide scientific and regulatory oversight.

The executive must consider relevant expert advice and comply with statutory requirements.

6. Important Case Laws

The following judgments establish important principles concerning constitutional authority, executive discretion and biotechnology approvals.

Case 1. Gene Campaign v. Union of India (2024) 2024 INSC 545

Most directly relevant Indian case

Court: Supreme Court of India.

Facts:

The case concerned approval granted by the Genetic Engineering Appraisal Committee (GEAC) for the environmental release of genetically modified mustard, known as DMH-11.

The petitioners challenged the approval on grounds including inadequate risk assessment, procedural irregularities, environmental concerns and violations of the precautionary principle.

Judgment:

The Supreme Court delivered a split verdict on 23 July 2024.

Justice B.V. Nagarathna considered the approval legally defective and favoured quashing it.

Justice Sanjay Karol upheld the approval and considered the regulatory decision within the domain of public policy.

The Court unanimously held that decisions of authorities concerning GMOs are subject to judicial review.

It also directed the Union Government to formulate a national policy on GM crops after consulting scientific experts, state governments, farmers and other stakeholders.

The Court addressed conflicts of interest among experts and the need for transparency in regulatory decisions.

S3WaaS+2

Legal significance:

This judgment establishes that:

Biotechnology approvals are subject to constitutional scrutiny.

Executive authorities must follow statutory procedures.

Scientific experts must disclose conflicts of interest.

Environmental risk assessments must be sufficiently comprehensive.

Government policy should incorporate stakeholder consultation.

Importantly, the split verdict did not itself produce a final majority ruling on the validity of the DMH-11 approval; that issue was referred for consideration by an appropriate larger bench.

Case 2. Vellore Citizens' Welfare Forum v. Union of India (1996) 5 SCC 647

Court: Supreme Court of India.

Facts:

The case concerned environmental pollution caused by tanneries and the resulting harm to water resources and public health.

Judgment:

The Supreme Court recognised the precautionary principle and polluter-pays principle as essential components of sustainable development.

Legal significance for biotechnology:

The principles are relevant to:

Environmental release of GM crops.

Gene-drive experiments.

Synthetic biology.

Genetically modified microorganisms.

Potentially irreversible ecological interventions.

The executive must take preventive measures even where scientific uncertainty exists and serious environmental damage is possible.

Indian Kanoon+1

Case 3. R (Miller) v. Secretary of State for Exiting the European Union [2017] UKSC 5

Court: United Kingdom Supreme Court.

Facts:

The dispute concerned whether the executive could use prerogative powers to initiate withdrawal from the European Union without parliamentary authorisation.

Judgment:

The Supreme Court held that ministers could not use prerogative powers to change domestic law or remove statutory rights without parliamentary authorisation.

Legal significance for biotechnology:

The judgment illustrates an important constitutional principle: executive powers must remain within the limits established by legislation.

Accordingly, a minister cannot independently disregard statutory biotechnology approval procedures or create regulatory powers that Parliament has not conferred.

Bailii

Case 4. Cross v. Information Commissioner and Cabinet Office [2016] UKUT 153 (AAC)

Court: United Kingdom Upper Tribunal.

Facts:

The dispute concerned whether the Sovereign and Royal Household constituted public authorities for the purposes of environmental information legislation.

Judgment:

The Tribunal distinguished the Sovereign's constitutional functions from the government's public administration and executive functions.

Legal significance:

This distinction is important in biotechnology governance because the monarch's constitutional position should not be confused with the statutory responsibilities of ministers and regulatory authorities.

The practical regulatory responsibility belongs to the relevant executive and administrative institutions.

GOV.UK

Case 5. Beyond GM v. Secretary of State for Environment, Food and Rural Affairs [2026] EWHC 1306 (Admin)

Important 2026 biotechnology decision

Court: High Court of Justice, England and Wales.

Decision date: 4 June 2026.

Facts:

The case challenged the regulatory framework introduced under the Genetic Technology (Precision Breeding) Act 2023 and the Genetic Technology (Precision Breeding) Regulations 2025.

The claimants raised concerns about environmental protection, transparency, traceability and the absence of mandatory labelling for precision-bred organisms and their food products.

Judgment:

The High Court allowed the judicial-review challenge on the irrationality ground.

An important issue was that government officials had incorrectly advised the minister that the 2023 Act did not provide power to introduce mandatory labelling.

The Court explained that the Act did provide a power to impose traceability requirements through labelling.

The Court refused permission on the other grounds, including the separate challenges concerning Convention rights, environmental assessment and statutory authority.

Legal significance:

This judgment demonstrates that:

Ministers must receive legally accurate advice.

Executive decisions must be based on a correct understanding of statutory powers.

Biotechnology deregulation must comply with public-law principles.

Consumer information and traceability are relevant regulatory considerations.

Judicial review can examine the legality of executive decisions concerning advanced biotechnology.

The Court allowed the claim on the irrationality ground, with consequential relief left for further submissions.

Bailii+1

7. Comparison Between Monarchy and Executive

8. Major Legal Issues and Challenges

A. Political interference

Political pressure may influence scientific assessments and approval decisions.

An executive authority must ensure that decisions are based on evidence, statutory considerations and public interest rather than political preferences alone.

B. Conflict between innovation and precaution

Biotechnology can offer significant benefits, including disease-resistant crops, improved medicines and advanced genetic therapies.

However, inadequate regulation may produce environmental or health risks.

The executive must balance innovation with precautionary regulation.

C. Regulatory accountability

Where an approval causes environmental or public-health damage, questions may arise concerning:

Responsibility of the approving authority.

Negligence in risk assessment.

Failure to conduct adequate inspections.

Inadequate post-approval monitoring.

Failure to disclose material safety information.

D. Federalism and state participation

In India, agriculture, environmental protection and public health involve different constitutional and statutory responsibilities.

Consequently, biotechnology decisions concerning agricultural releases should take account of relevant state interests and local environmental conditions.

The 2024 Gene Campaign judgment particularly emphasised stakeholder and state-government participation in national GM-crop policy.

E. Transparency and public participation

The executive must establish appropriate procedures for public consultation, access to regulatory information, disclosure of scientific conflicts of interest and review of approval decisions.

Transparency strengthens public confidence in biotechnology regulation.

9. International Legal Principles

Several international instruments influence biotechnology approvals.

1. Cartagena Protocol on Biosafety, 2000

Establishes an international framework for the safe handling, transfer and use of living modified organisms, particularly those resulting from modern biotechnology.

2. Convention on Biological Diversity, 1992

Promotes biodiversity conservation, sustainable use and fair benefit-sharing.

3. Universal Declaration on Bioethics and Human Rights, 2005

Provides ethical principles concerning human dignity, informed consent, equality and responsibility in biological and medical research.

4. WTO Agreement on Sanitary and Phytosanitary Measures

Provides rules concerning measures protecting human, animal and plant life or health, including certain biotechnology-related trade restrictions.

These instruments guide national governments in designing scientifically justified, transparent and internationally compatible approval systems.

10. Suggestions for Improving Biotechnology Approval Governance

The following reforms can strengthen the relationship between constitutional institutions and executive authorities:

Establish independent scientific review committees.

Introduce transparent approval procedures.

Require disclosure of conflicts of interest.

Strengthen environmental impact assessments.

Introduce appropriate public consultation mechanisms.

Establish independent post-approval monitoring.

Provide effective appeal and judicial-review mechanisms.

Strengthen parliamentary supervision of biotechnology policy.

Ensure coordination between national and state authorities.

Establish clear accountability for unlawful approvals and regulatory failures.

11. Conclusion

The role of monarchy and executive in biotechnology approvals must be understood through constitutional and administrative law.

In a constitutional monarchy, the monarch generally performs formal constitutional functions, including royal assent, while the executive exercises substantive governmental and regulatory powers.

In India, which is a constitutional republic, biotechnology approvals are administered through statutory authorities, ministries and scientific regulatory institutions.

The judgments in Gene Campaign v. Union of India (2024), Vellore Citizens' Welfare Forum v. Union of India (1996), Miller (2017) and Beyond GM v. Secretary of State (2026) demonstrate that biotechnology governance must respect legality, scientific integrity, environmental protection, transparency and public accountability.

The fundamental legal principle is that neither constitutional authority nor executive discretion can replace statutory compliance, scientific evaluation and judicially enforceable safeguards in biotechnology approvals.

12. Important Cases for Examination and Research

Research note: The distinction between ceremonial monarchy and substantive executive power is particularly important when comparing the United Kingdom with India. The cases above are relevant to constitutional and administrative control of biotechnology, although not all directly concern royal authority or the granting of individual biotechnology licences.